Viral Keratitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Viral Keratitis – Drugs In Development, 2024 report and make more profitable business decisions.
Viral infection of the cornea is often caused by the herpes simplex virus (HSV) which frequently leaves what is called a ‘dendritic ulcer’. Keratitis is a condition in which the eye’s cornea, the clear dome on the front surface of the eye, becomes inflamed. The condition is often marked by moderate to intense pain and usually involves any of the following symptoms: pain, impaired eyesight, photophobia (light sensitivity), red eye and a ‘gritty’ sensation.
The Viral Keratitis drugs in development market research report provide comprehensive information on the therapeutics under development for Viral Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Keratitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Viral Keratitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Viral Keratitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Viral Keratitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Viral Keratitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cumulus Pharmaceutical LLCEditas Medicine Inc
Fox Chase Chemical Diversity Center Inc
Marinomed Biotech AG
NanoViricides Inc
Shanghai BDgene Therapeutics Co Ltd
Shulov Innovative Science Ltd
Stowe Pharmaceuticals Inc
Trefoil Therapeutics LLC
Viraze
Zhejiang Raytone Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Viral Keratitis reports